Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Sourced facts

• Antibody-drug conjugate program HDM2024: ClinicalTrials.gov lead sponsor (1 trial) · clinicaltrials.gov/study/NCT07539285 · checked Oct 20, 2026
• “HDM2024 for injection is a Class 1 innovative biologic independently developed by Zhongmei Huadong with global intellectual property rights” · en.huadongmedicine.com · checked Oct 20, 2026